Summary
Guardant Health, Inc. reported a 31% increase in total revenue for the first quarter of 2024, reaching $168.5 million, driven primarily by a 38% surge in precision oncology testing revenue to $156.2 million. This growth was fueled by higher test volumes and improved reimbursement rates, particularly for their Guardant360 LDT and CDx tests. Despite the top-line growth, the company continued to operate at a significant net loss of $115.0 million, though this was an improvement from the $133.5 million loss in the prior year's quarter. The company's substantial cash reserves of $1.1 billion provide a strong liquidity position, enabling continued investment in research and development, including advancements in early cancer detection tests like Shield for colorectal and lung cancer.
Financial Highlights
53 data points| Revenue | $168.49M |
| Cost of Revenue | $65.30M |
| Gross Profit | $103.19M |
| R&D Expenses | $83.80M |
| Operating Expenses | $268.17M |
| Operating Income | -$99.68M |
| Interest Expense | $645K |
| Net Income | -$114.98M |
| EPS (Basic) | $-0.94 |
| EPS (Diluted) | $-0.94 |
| Shares Outstanding (Basic) | 121.71M |
| Shares Outstanding (Diluted) | 121.71M |
Key Highlights
- 1Total revenue increased by 31% year-over-year to $168.5 million in Q1 2024.
- 2Precision oncology testing revenue grew by 38% to $156.2 million, driven by increased sample volume and improved reimbursement rates.
- 3Net loss improved to $115.0 million from $133.5 million in the same period last year.
- 4The company maintained a strong liquidity position with $1.1 billion in cash, cash equivalents, and restricted cash as of March 31, 2024.
- 5Research and development expenses decreased by 10% to $83.8 million, reflecting a strategic shift in spending.
- 6Sales and marketing expenses increased by 6% to $80.4 million, indicating continued investment in market expansion.
- 7The Shield LDT test for colorectal cancer screening is progressing towards an FDA review in May 2024.